Table 2.
Univariate and multivariate logistic regression analysis of HBsAg-positive DLBCL patients
| Factor | Median Overall survival (months) | p-value in univariate analysis | p-value in multivariate analysis |
| Sex | 0.96 | - | |
| Male | 50 | ||
| Female | 55.9 | ||
| HBeAg | - | ||
| + | NA | 0.39 | |
| - | 55.9 | ||
| Staging | 0.001 | < 0.001 | |
| I | 13 | ||
| II | 21 | ||
| III | 23 | ||
| IV | 24 | ||
| B symptom | 0.2 | - | |
| Yes | NA | ||
| No | 55.9 | ||
| Age(years) | 0.21 | - | |
| > 60 | NA | ||
| ≤ 60 | 55.9 | ||
| LDH | 0.17 | - | |
| > normal | 46.7 | ||
| normal | 55.9 | ||
| Extranodal sites | 0.47 | - | |
| > 1 | 37.5 | ||
| 0–1 | 55.9 | ||
| PS | 0.23 | - | |
| 0–1 | 55.8 | ||
| 2–4 | NA | ||
| Radiation therapy | 0.004 | 0.093 | |
| Yes | NA | ||
| No | 46.7 | ||
| Pre-CT hepatic dysfunction | 0.66 | - | |
| Yes | NA | ||
| No | 55.9 | ||
| Intra-CT hepatic dysfunction | 0.016 | 0.02 | |
| Yes | 46.7 | ||
| No | NA | ||
| Rituximab | 0.5 | - | |
| Yes | NA | ||
| No | 55.9 |